ICER released its draft evidence report on beta-amyloid antibodies for early Alzheimer’s disease.
ICER has redefined the scope of this review multiple times since it was first announced over a year ago. Multiple edits to both the timeline and the interventions of interest make meaningful participation in the process difficult.
